Metagenomi reports $140.2M cash; MGX-001 IND on track for Q4 2026

Metagenomi Therapeutics, Inc.

2026-Q1 EPS reported -$0.61 revenue$1,248,000

Cash, equivalents and marketable securities of $140.2M at March 31, 2026; runway through Q4 2027.
MGX-001 for hemophilia A: regulatory submission including IND planned for Q4 2026, first-in-human trials in 2027.
Kapil Saxena, MD, appointed to lead clinical development for MGX-001; prior roles at Autolus, Bayer, Daiichi Sankyo.
R&D expenses $19.3M in Q1 2026 (vs $25.1M Q1 2025); G&A $6.5M (vs $6.8M).
Nature publication on compact CRISPR nuclease MG119-28 with enhanced editing efficiency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.